Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Javier Munoz, MD, Samantha Jaglowski, MDMPH, Matthew S. McKinney, MD, Iris Isufi, MD, Patrick J. Stiff, MD, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Luke P. Akard, MD

Blood (2019) 134 (Supplement_1): 244.

https://doi.org/10.1182/blood-2019-123810

Published: 2019

Journal Articles

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

Ian W. Flinn, MD PhD, Jason R. Westin, MD, Jonathon B. Cohen, MDMS, Luke P. Akard, MD, Samantha Jaglowski, MDMPH, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Veronika Bachanova, MD PhD

Blood (2019) 134 (Supplement_1): 1587.

https://doi.org/10.1182/blood-2019-125995

Published: 2019

Journal Articles

Preliminary Clinical Results of a Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B-Cell Lymphoma

Ian W. Flinn, MD PhD, Jonathon B. Cohen, MD MS, Luke P. Akard, MD, Samantha Jaglowski, MD MPH, Michael Vasconcelles, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Greg Motz, PhD, Veronika Bachanova, MD PhD

Blood (2018) 132 (Supplement 1): 2966.

https://doi.org/10.1182/blood-2018-99-111622

Published: 2018

Journal Articles

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Don M. Benson, Jr., MD PhD, Houston Holmes, MD, Parameswaran Hari, MBBS, MD, Jessica Sachs, MD, Ben Exter, Ann Ranger, PhD, Tooba Cheema, PhD, Iga Sienczylo, BS, Megan M. O'Meara, MD, Django Sussman, PhD, Luke P. Akard, MD

Blood (2018) 132 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2018-99-111729

Published: 2018

Journal Articles

Donor Lymphocyte Infusions Used to Treat Mixed Chimerism in Relapsed and Non-Relapsed Patient Populations after Allogeneic Transplant for Hematologic Malignancies Are Associated with High 5-Year Survival If Persistent Full Donor Chimerism Is Obtained

Lauren E Caldemeyer, BA, Luke P Akard, MD, John R Edwards, MD, Michael J Dugan, MD

Blood (2016) 128 (22): 3443.

https://doi.org/10.1182/blood.V128.22.3443.3443

Published: 2016

Journal Articles

Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,

Jorge E. Cortes, Franck E. Nicolini, MD, PhD, Meir Wetzler, MD, Jeffrey H. Lipton, MD, PhD, Luke P. Akard, MD, Adam Craig, MD, PhD, Nisha Nanda, PhD, Carrie Dial, BS, Annie-Claude Benichou, MD, Katie Cairati, MS, Michele Baccarani, MD, Gerard T. Kennealey, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 3761.

https://doi.org/10.1182/blood.V118.21.3761.3761

Published: 2011

Journal Articles

Effect of Switching to Nilotinib in Patients with Imatinib-Related Low-Grade Non-Hematologic Adverse Events

Jeffrey H. Lipton, MD, PhD, Michael J. Mauro, MD, Sikander Ailawadhi, MD, Carole B. Miller, MD, Lambert Busque, MD, Luke P. Akard, MD, Javier Pinilla-Ibarz, MD, PhD, Solveig G. Ericson, MD- PhD, Jinay Shah, MS, Jorge E. Cortes

Blood (2011) 118 (21): 4422.

https://doi.org/10.1182/blood.V118.21.4422.4422

Published: 2011

Journal Articles

Effect of Nilotinib (NIL) on Molecular Response in Chronic Myelogenous Leukemia - Chronic Phase (CML-CP) Patients (pts) with a Suboptimal Molecular Response to Imatinib (IM)–ENABL Study Update

Sikander Ailawadhi, MD, Carole B. Miller, MD, Anand P. Jillella, MD, Nebu Koshy, MD, Brian Tudor, MD, Luke P. Akard, MD, Solveig G. Ericson, MD- PhD, Felice P. Lin, PharmD, Jerald P. Radich, MD, Daniel J. DeAngelo, MD, PhD

Blood (2011) 118 (21): 2771.

https://doi.org/10.1182/blood.V118.21.2771.2771

Published: 2011

Journal Articles

Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib.

Allen S. Yang, MD, PhD, Anand Jillella, MD, Carole B. Miller, MD, Luke P. Akard, MD, Daniel J. DeAngelo, MD, PhD, Stuart L. Goldberg, MD, Denise Williams, MD, Jerald P. Radich, MD

Blood (2009) 114 (22): 2206.

https://doi.org/10.1182/blood.V114.22.2206.2206

Published: 2009

Journal Articles

Is Splenectomy Necessary in Patients with Myelofibrosis and Extensive Splenomegaly Prior to Allogeneic Stem Cell Transplantation with Reduced Intensity Conditioning Regimens?.

Stefan O. Ciurea, MD, Barry Sadegi, MD, Andrew Wilbur, MD, Victoria Alagiozian-Angelova, MD, Sujata Gaitonde, MD, Lisa C. Dobogai, RN, NP, Luke P. Akard, MD, Ronald Hoffman, MD, Damiano Rondelli, MD

Blood (2007) 110 (11): 1091.

https://doi.org/10.1182/blood.V110.11.1091.1091

Published: 2007

Journal Articles

Treatment with AMD3100 in Multiple Myeloma or Non-Hodgkin’s Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given with a Mobilizing Regimen of Chemotherapy and G-CSF.

Michael J. Dugan, MD, Luke P. Akard, MD, James M. Thompson, DO, Auayporn Nademanee, MD, Richard T. Maziarz, MD, William I. Bensinger, MD, Jane Liesveld, MD, Karin Badel, Christine Dehner, Colleen Gibney, Gary Calandra, Jan Jansen, MD, PhD

Blood (2004) 104 (11): 2860.

https://doi.org/10.1182/blood.V104.11.2860.2860

Published: 2004

NARROW

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20 + non-Hodgkin Lymphoma

Preliminary Clinical Results of a Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B-Cell Lymphoma

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Donor Lymphocyte Infusions Used to Treat Mixed Chimerism in Relapsed and Non-Relapsed Patient Populations after Allogeneic Transplant for Hematologic Malignancies Are Associated with High 5-Year Survival If Persistent Full Donor Chimerism Is Obtained

Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,

Effect of Switching to Nilotinib in Patients with Imatinib-Related Low-Grade Non-Hematologic Adverse Events

Effect of Nilotinib (NIL) on Molecular Response in Chronic Myelogenous Leukemia - Chronic Phase (CML-CP) Patients (pts) with a Suboptimal Molecular Response to Imatinib (IM)–ENABL Study Update

Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib.

Is Splenectomy Necessary in Patients with Myelofibrosis and Extensive Splenomegaly Prior to Allogeneic Stem Cell Transplantation with Reduced Intensity Conditioning Regimens?.

Treatment with AMD3100 in Multiple Myeloma or Non-Hodgkin’s Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given with a Mobilizing Regimen of Chemotherapy and G-CSF.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only